Tap a claim on the ring to put it at the centre.
← Biotech R&D efficiency and pharma R&D efficiency are not the same thing and should not be conflated.
17 connected korrents · 16 moments from 15 Jul 2021 to 25 Oct 2026.
Everything filed under creativity
creativity
Everything filed under innovation
innovation
Everything filed under LLMs
LLMs
Everything filed under design
design
Everything filed under protein structure prediction
protein structure prediction
Everything filed under AI and science
AI and science
Everything filed under infrastructure
infrastructure
Everything filed under startups
startups
Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject
Read this korrent: Biotech R&D efficiency and pharma R&D efficiency are not the same thing and should not be conflated.
Biotech R&D efficiency and pharma R&D efficiency are not the same thing and should not be conflated.
Last stated 7 months ago
12 Apr 2026
EH
Elliot Hershberg — holds since 2026-04-12 — tap for who they are
Same subject: Drug discovery has become less efficient over time despite continued technological progress. — tap to centre the map on it
Drug discovery has become less efficient over time despite continued technological progress.
Last stated 10 months ago
18 Jan 2026
EH
Elliot Hershberg — holds since 2026-01-18 — tap for who they are
Same subject: New technologies can meaningfully improve R&D productivity in drug development. — tap to centre the map on it
New technologies can meaningfully improve R&D productivity in drug development.
Last stated 7 months ago
12 Apr 2026
EH
Elliot Hershberg — holds since 2026-04-12 — tap for who they are
Same subject: AI infrastructure companies that sell tools rather than drugs can become massive, highly valuable businesses in biotech. — tap to centre the map on it
AI infrastructure companies that sell tools rather than drugs can become massive, highly valuable businesses in biotech.
Last stated 12 months ago
23 Nov 2025
EH
Elliot Hershberg — holds since 2025-11-23 — tap for who they are
Same subject: The amount spent on R&D should not be assumed to be a useful measure of its output. — tap to centre the map on it
The amount spent on R&D should not be assumed to be a useful measure of its output.
Last stated 3 years ago
21 Feb 2024
PC
Patrick Collison — holds since 2024-02-21 — tap for who they are
Same subject: Pharmaceutical R&D productivity has fallen for decades: far more money spent per drug, with no matching improvement in the odds a candidate reaches the market. — tap to centre the map on it
Pharmaceutical R&D productivity has fallen for decades: far more money spent per drug, with no matching improvement in the odds a candidate reaches the market.
Last stated 4 months ago
21 Jul 2026
AT
Alex Telford — holds since 2023-12-23 — tap for who they are
RT
Ruxandra Teslo — holds since 2026-07-21 — tap for who they are
Same subject: Better drug candidates do not shorten clinical trials, because a trial's duration is set by operational and regulatory friction rather than by how good the drug is. — tap to centre the map on it
Better drug candidates do not shorten clinical trials, because a trial's duration is set by operational and regulatory friction rather than by how good the drug is.
Last stated 9 months ago
28 Feb 2026
RT
Ruxandra Teslo — holds since 2026-02-28 — tap for who they are
Same subject: Many biotech companies have no factual basis and exist mainly to raise money to pay salaries. — tap to centre the map on it
Many biotech companies have no factual basis and exist mainly to raise money to pay salaries.
Last stated 4 weeks ago
25 Oct 2026
VP
Vinay Prasad — holds since 2026-10-25 — tap for who they are
Same subject: The biopharma industry is structured to focus on only a limited number of disease areas. — tap to centre the map on it
The biopharma industry is structured to focus on only a limited number of disease areas.
Last stated 2 years ago
20 May 2025
EG
Elad Gil — holds since 2025-05-20 — tap for who they are
Same subject: A narrow, highly accurate model can beat a general one inside its own domain, as AlphaFold did, and materials science and chip design are next. — tap to centre the map on it
A narrow, highly accurate model can beat a general one inside its own domain, as AlphaFold did, and materials science and chip design are next.
Last stated 4 months ago
30 Jul 2026
JD
Jeff Dean — holds since 2026-07-30 — tap for who they are
Same subject: Contemporary physical and evolutionary structure-prediction approaches fall far short of experimental accuracy without a close experimental homologue, limiting biological utility. — tap to centre the map on it
Contemporary physical and evolutionary structure-prediction approaches fall far short of experimental accuracy without a close experimental homologue, limiting biological utility.
Last stated 5 years ago
15 Jul 2021
DH
Demis Hassabis — holds since 2021-07-15 — tap for who they are
Same subject: Deep learning has effectively solved the problem of predicting a protein's 3D structure from its sequence. — tap to centre the map on it
Deep learning has effectively solved the problem of predicting a protein's 3D structure from its sequence.
Last stated a year ago
29 Jun 2025
EH
Elliot Hershberg — holds since 2025-06-29 — tap for who they are
Same subject: A contest between five paid firms is not the way to get good creative work. — tap to centre the map on it
A contest between five paid firms is not the way to get good creative work.
Last stated 3 months ago
14 Aug 2026
SK
Susan Kare — holds since 2026-08-14 — tap for who they are
Same subject: A culture that is uncompromising but also kind and supportive is the most fertile ground for creativity. — tap to centre the map on it
A culture that is uncompromising but also kind and supportive is the most fertile ground for creativity.
Last stated 7 months ago
12 Apr 2026
ES
Evan Spiegel — holds since 2026-04-12 — tap for who they are
Same subject: A feeling of responsibility is probably the greatest inhibitor of creativity; great ideas came from people not paid to have them — tap to centre the map on it
A feeling of responsibility is probably the greatest inhibitor of creativity; great ideas came from people not paid to have them
IA
Isaac Asimov — holds since c. 1959 — tap for who they are
Same subject: "Return on tokens" has the same measurement problems as hours and capacity: it still hinges on a theory of value. — tap to centre the map on it
"Return on tokens" has the same measurement problems as hours and capacity: it still hinges on a theory of value.
Last stated 3 months ago
17 Aug 2026
JC
John Cutler — holds since 2026-08-17 — tap for who they are
Same subject: A badly written AI outbound email is evidence of a bad vendor, not of a limit of AI. — tap to centre the map on it
A badly written AI outbound email is evidence of a bad vendor, not of a limit of AI.
Last stated 11 months ago
1 Jan 2026
JL
Jason Lemkin — holds since 2026-01-01 — tap for who they are
Same subject: A base model is essentially a very expensive autocomplete that continues text according to the statistics of its training documents. — tap to centre the map on it
A base model is essentially a very expensive autocomplete that continues text according to the statistics of its training documents.
Last stated 2 years ago
5 Feb 2025
AK
Andrej Karpathy — holds since 2025-02-05 — tap for who they are
same subject or similar wording a cloud: claims about one subject, named for it bar: when it was last stated, on a scale from 2015 to today — full is today a face: someone who holds the claim — tap it for who they are